12,341 Shares of iShares U.S. Pharmaceuticals ETF $IHE Bought by Strategy Asset Managers LLC

Strategy Asset Managers LLC bought a new stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 12,341 shares of the company’s stock, valued at approximately $1,241,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Trust Co. of Vermont acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the second quarter worth about $60,000. Root Financial Partners LLC boosted its stake in shares of iShares U.S. Pharmaceuticals ETF by 36.5% in the first quarter. Root Financial Partners LLC now owns 696 shares of the company’s stock valued at $60,000 after purchasing an additional 186 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF in the second quarter valued at approximately $75,000. Valley Wealth Managers Inc. purchased a new position in shares of iShares U.S. Pharmaceuticals ETF in the third quarter valued at approximately $90,000. Finally, Sunbelt Securities Inc. grew its holdings in shares of iShares U.S. Pharmaceuticals ETF by 14.3% in the first quarter. Sunbelt Securities Inc. now owns 960 shares of the company’s stock valued at $83,000 after purchasing an additional 120 shares in the last quarter.

iShares U.S. Pharmaceuticals ETF Stock Performance

Shares of IHE stock opened at $99.49 on Thursday. The stock has a market capitalization of $1.54 billion, a P/E ratio of 17.75 and a beta of 0.47. The company has a 50 day moving average price of $102.55 and a 200 day moving average price of $96.44. iShares U.S. Pharmaceuticals ETF has a fifty-two week low of $73.42 and a fifty-two week high of $108.66.

About iShares U.S. Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.